Vizzutti F, Rega L, Arena U, Giulio RR, Meucci F, Barletta G, Schepis F, Tsalouchos A, Laffi G, Marra F

Language: English
References: 13
Page: 127-131
PDF size: 154.73 Kb.

ABSTRACT

No definitive indications are provided in the literature for pre-TIPS patient workup, which is often limited to prevent the incidence of refractory hepatic encephalopathy or unacceptable deterioration of liver function. Concerning cardiologic workup, efforts are generally limited at excluding ventricular failure or porto-pulmonary hypertension. The cases presented herein focus the attention of the readers on the possible occurrence of post-TIPS paradoxical embolization in the presence of a patent foramen ovale, frequently recognized in adult population. In conclusion, although this complication has been already reported in literature, in the present manuscript we concentrate on possible additional risk factors which may allow to identify a subset of patients with a higher likelihood to experience paradoxical embolization following TIPS. Another important line of information presented herein is the feasibility of percutaneous closure of a patent foramen ovale before TIPS deployment in the presence of portal vein thrombosis and possibly with additional risk factors.

REFERENCES

1. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010; 24: 2370-9.

2. Salerno F, Cammŕ C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-34.

3. Rossle M. TIPS: 25 years later. J Hepatol 2013; 59: 1081-93.

4. Azoulay D, Castaing D, Dennison A, Martino W, Eyraud D, Bismuth H. Transjugular intrahepatic portosystemic shunt worsens the hyperdynamic circulatory state of the cirrhotic patient: preliminary report of a prospective study. Hepatology 1994; 19: 129-32.

5. der Linden P Van, Le Moine O, Ghysels M, Ortinez M, Deviere J. Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. Hepatology 1996; 23: 982-7.

6. Homma S, Sacco RL. Patent foramen ovale and stroke. Circulation 2005; 16: 1063-72.

7. Seib GA. Incidences of the patent foramen ovale cordis in adult American whites and American Negroes. Am J Anat 1934; 55: 511-25.

8. Tuennemann J, Mossner J, Hoffmeister A. Acute cerebrovascular incident as a complication of TIPS procedure. Z Gastroenterol 2013; 51: 381-3.

9. Appenrodt B, Schepke M, Kuntz-Hehner S, Schmiedel A, Sauerbruch T. A patient with portal hypertension and blindness after transjugular intrahepatic portosystemic shunt. Eur J Gastroenterol Hepatol 2006; 18: 447-9.

10. Lam YY, Yu CM, Zhang Q, Yan BP, Yip GW. Enhanced detection of patent foramen ovale by systematic transthoracic saline contrast echocardiography. Int J Cardiol 2011; 152: 24-7.

11. Braun M, Gliech V, Boscheri A, Schoen S, Gahn G, Reichmann H, Haass M, et al. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occlude systems. Eur H J 2004; 25: 424-30.

12. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, et al. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013; 368: 1083-91.

13. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, Mac- Donald LA, Marks DS, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013; 368: 1092-100.